Navigation Links
OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan
Date:5/28/2008

HONG KONG, May 28 /PRNewswire/ -- OrbusNeich today announced that it has received approval from the Department of Health to market the Genous Bio-engineered R stent in Taiwan.

The Genous stent is coated with an antibody to capture a patient's endothelial progenitor cells (EPCs) circulating in the bloodstream. When attracted to the inner surface of the Genous stent, EPCs have been shown to quickly form a healthy layer of endothelium that minimizes stent restenosis and provides protection against stent thrombosis.

"We are pleased to be able to offer the Genous stent to interventional cardiologists in Taiwan," said Teddy Chien, OrbusNeich's chairman. "The introduction of our pro-healing stent to the Taiwanese market is an important step for our company as we expand our presence in the Asia-Pacific region. Based on our interaction with Taiwanese physicians, we expect strong Genous sales from the outset because of the demand for safe alternatives to drug-eluting stents."

An estimated 20,000 coronary angioplasty procedures will be performed in Taiwan in 2008, 60% of which are expected to involve the use of drug eluting or coated stents.

"We are pleased to have Genous stents become available in Taiwan," said Jui-Sung Hung, M.D., FACC, FAHA, founding President of the Taiwan Society of Cardiovascular Interventions. "Preliminary studies have shown that the use of Genous stents is as safe and effective as TAXUS DES, and more importantly, that the stent thrombosis rate at 12 months is lower with the Genous stent despite one month of dual antiplatelet therapy. Although results of large-scale, randomized control trials are awaited to make more definitive conclusions, I believe Genous will be a good treatment option for patients who cannot undergo long-term dual antiplatelet therapy or patients who have increased risk of thrombotic events."

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

As a global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
2. OrbusNeich Receives CE Mark Approval for Sapphire(TM) 1.25MM PTCA Dilatation Catheter
3. 5,000 Patients Treated With OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
4. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
5. Cornell receives federal grants to create fabrics to render toxic chemicals harmless
6. Einstein-Montefiore Center for AIDS Research receives $8.5M award from NIH
7. Somanetics Receives 510(k) Clearance From the FDA to Expand INVOS System Labeling
8. TriWest Receives National Awards for Innovative Video Communications to Military Community
9. A.S.V., Inc. Receives Safety and Health Award
10. Dr. Michael Brownlee receives JDRF Rumbough Award for Scientific Excellence
11. LMI Receives CDC/ATSDR Public Health Improvement Award for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... and accessories. These PEEK-lined stainless steel (PLS) columns combine the strength of traditional ... ensures the integrity of biological samples while operating at ultra-high pressures of 20,000 ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over steep cost ... Part D a decade ago, according to The Senior Citizens League (TSCL). ... they are coping with rapidly rising costs. “The implications are chilling, particularly for ...
(Date:2/10/2016)... ... February 09, 2016 , ... Traumatic Brian Injury ... injury may be one of many possible sources: sports, car accidents, falls, work ... , Mastering Rehab Solutions for the Complexities of Concussions is designed ...
(Date:2/9/2016)... ... February 09, 2016 , ... February is Heart Awareness Month, and ... scans throughout the month to the American Heart Association, New Mexico chapter. , A ... heart disease and Health Quest’s INSiGHT Pulse Wave Profiler utilizes a non-invasive technology to ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... announces today the continuation of the ‘Pay It Forward’ program into 2016. BioPlus ... received at our specialty pharmacy. , “Since our Pay It Forward program ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 --> ... and Companion Diagnostic Market to 2019 - Strategic ... research report indicates that the core personalized medicine ... 2020 growing at a CAGR of 8.74%. This ... targeted therapeutics and is dominated by oncology, cardiovascular ...
(Date:2/10/2016)... , February 10, 2016 ... M 1 receptor selectivity   ... technology, which has entered clinical development as a ... dementia and schizophrenia.   --> 1 ... which has entered clinical development as a new ...
(Date:2/9/2016)... 9, 2016  Misonix, Inc. (NASDAQ: MSON ... manufactures and markets innovative therapeutic ultrasonic products for ... surgery, laparoscopic surgery and other surgical applications, today ... the first half of fiscal year 2016 ended ... --> Highlights for the second ...
Breaking Medicine Technology: